Submissions from 2021
Primary thromboprophylaxis in a patient with type 3 von Willebrand disease and severe COVID-19 infection, A. Vagrecha, J. Stanco, S. Majeed, P. Kouides, and S. S. Acharya
Submissions from 2020
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients, B. Alman, S. Attia, C. Baumgarten, C. Benson, J. Blay, S. Bonvalot, J. Breuing, K. Cardona, R. Maki, N. Zafiropoulos, and +47 additional authors
Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A, M. Bill, K. Mrózek, J. Kohlschmidt, A. K. Eisfeld, C. J. Walker, D. Nicolet, D. Papaioannou, J. S. Blachly, J. E. Kolitz, C. D. Bloomfield, and +6 additional authors
Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia, M. Bill, D. Nicolet, J. Kohlschmidt, C. J. Walker, K. Mrózek, A. K. Eisfeld, D. Papaioannou, X. Rong-Mullins, J. E. Kolitz, C. D. Bloomfield, and +8 additional authors
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer, J. W. Clark, D. R. Camidge, E. L. Kwak, R. G. Maki, G. I. Shapiro, I. Chen, W. Tan, S. Randolph, J. G. Christensen, R. Salgia, and +3 additional authors
Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas, A. R. Dancsok, D. Gao, A. F. Lee, S. E. Steigen, J. Blay, D. M. Thomas, R. G. Maki, T. O. Nielsen, and E. G. Demicco
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network, G. D. Demetri, C. R. Antonescu, B. Bjerkehagen, J. V. Bovee, K. Boye, M. Chacon, A. P. Dei Tos, J. Desai, R. Maki, J. Blay, and +38 additional authors
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 >years, A. K. Eisfeld, J. Kohlschmidt, A. Mims, D. Nicolet, C. J. Walker, J. S. Blachly, A. J. Carroll, D. Papaioannou, J. E. Kolitz, C. D. Bloomfield, and +5 additional authors
Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma., K. R. Gundle, G. B. Deutsch, H. J. Goodman, S. M. Pollack, M. J. Thompson, J. L. Davis, M. Lee, D. C. Ramirez, W. Kerwin, R. G. Maki, and +8 additional authors
Identifying patterns of failure and secondary primary malignancies in HPV-related oropharyngeal squamous cell carcinomas, R. Holstead, R. Rasul, A. Golden, D. Kamdar, M. Ghaly, S. Teckie, D. Frank, J. Fantasia, and N. Seetharamu
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia, J. E. Kolitz, S. A. Strickland, J. E. Cortes, D. Hogge, J. E. Lancet, S. L. Goldberg, K. F. Villa, R. J. Ryan, M. Chiarella, R. K. Stuart, and +2 additional authors
Bevacizumab-induced dysphonia: A case report with brief review of literature, S. Y. Lam, C. S. Lee, S. Sharma, and K. Cheng
A comprehensive review of contemporary literature for epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer and their toxicity, C. S. Lee, S. Sharma, E. Miao, C. Mensah, K. Sullivan, and N. Seetharamu
Lorlatinib induced proteinuria: A case report, C. Lee, R. Wanchoo, and N. Seetharamu
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801, G. Marcucci, S. Geyer, K. Laumann, W. Zhao, D. Bucci, G. L. Uy, W. Blum, A. K. Eisfeld, J. E. Kolitz, R. A. Larson, and +7 additional authors
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology, M. J. Markham, K. Wachter, N. Agarwal, M. M. Bertagnolli, S. M. Chang, W. Dale, C. S. Diefenbach, C. Rodriguez-Galindo, R. G. Maki, S. N. Westin, and +16 additional authors
Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic, J. Martin-Broto, N. Hindi, S. Aguiar, R. Badilla-Gonzalez, V. Castro-Oliden, M. Chacon, R. Correa-Generoso, E. de alava, R. Maki, J. Blay, and +25 additional authors
Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations, A. S. Mims, J. Kohlschmidt, A. K. Eisfeld, K. Mrόzek, J. S. Blachly, S. Orwick, D. Papaioannou, D. Nicolet, J. E. Kolitz, C. D. Bloomfield, and +4 additional authors
Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia, A. B. Moffitt, M. S. Spector, P. Andrews, J. Kendall, J. Alexander, A. Stepansky, J. Kolitz, N. Chiorazzi, S. L. Allen, Z. Wang, and +4 additional authors
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia, J. M. Pagel, M. Othus, G. Garcia-Manero, M. Fang, J. P. Radich, D. A. Rizzieri, G. Marcucci, S. A. Strickland, R. L. Bayer, F. R. Appelbaum, and +10 additional authors
Clinical and functional significance of circular RNAs in cytogenetically normal AML, D. Papaioannou, S. Volinia, D. Nicolet, M. Swierniak, A. Petri, K. Mrozek, M. Bill, F. Pepe, J. E. Kolitz, R. Garzon, and +10 additional authors
Association Between Pretreatment Sleep Disturbance and Radiation Therapy-Induced Pain in 573 Women With Breast Cancer, A. R. Peoples, W. R. Pigeon, D. Li, S. N. Garland, M. L. Perlis, J. E. Inglis, V. Vinciguerra, T. Anderson, L. S. Evans, J. R. Wolf, and +3 additional authors
Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes, J. M. Rhodes, V. A. LoRe, A. R. Mato, E. A. Chong, J. C. Barrientos, J. N. Gerson, S. K. Barta, D. J. Landsburg, S. D. Nasta, S. J. Schuster, and +2 additional authors
A Randomized,Double-Blind,Placebo-Controlled, PhaseIIStudy of Regorafenib Versus Placebo in Advanced/Metastatic,Treatment-RefractoryLiposarcoma: Results from theSARC024Study, R. F. Riedel, K. Ballman, Y. Lu, S. Attia, E. T. Loggers, K. N. Ganjoo, M. B. Livingston, W. Chow, J. Wright, R. G. Maki, and +10 additional authors
A framework for advancing our understanding of cancer-associated fibroblasts, E. Sahai, I. Astsaturov, E. Cukierman, D. G. DeNardo, M. Egeblad, R. M. Evans, D. Fearon, R. G. Maki, D. C. Ramirez, Z. Werb, and +10 additional authors
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia, I. G. Solman, L. K. Blum, H. Y. Hoh, T. J. Kipps, J. A. Burger, J. C. Barrientos, S. O'Brien, S. P. Mulligan, N. E. Kay, A. Mongan, and +4 additional authors
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration., D. M. Stephens, K. Boucher, E. Kander, S. A. Parikh, E. M. Parry, M. Shadman, J. M. Pagel, J. Cooperrider, J. Rhodes, J. C. Byrd, and +11 additional authors
Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer, A. M. Tufano, E. Teplinsky, and C. A. Landry
Submissions from 2019
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma, N. E. Berlow, R. Rikhi, M. Geltzeiler, J. Abraham, M. N. Svalina, L. E. Davis, E. Wise, M. Mancini, R. G. Maki, C. Keller, and +19 additional authors
Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21, B. Bhatnagar, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, D. Nicolet, D. Papaioannou, C. J. Walker, S. Orwick, J. E. Kolitz, C. D. Bloomfield, and +5 additional authors
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study, J. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D. R. D'Adamo, Y. Jia, and R. G. Maki
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas, A. R. Dancsok, N. Setsu, D. Gao, J. Y. Blay, D. Thomas, R. G. Maki, T. O. Nielsen, and E. G. Demicco
Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)., D. Dao, T. Zemla, A. Jatoi, R. A. Freedman, A. Hurria, H. Muss, H. J. Cohen, M. Citron, D. Budman, J. G. Le-Rademacher, and +6 additional authors
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma, L. E. Davis, V. Bolejack, C. W. Ryan, K. N. Ganjoo, E. T. Loggers, S. Chawla, M. Agulnik, M. B. Livingston, D. Reed, R. G. Maki, and +7 additional authors
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas, R. L. Jones, S. P. Chawla, S. Attia, P. Schoffski, H. Gelderblom, B. Chmielowski, A. Le Cesne, B. A. Van Tine, J. C. Trent, R. G. Maki, and +7 additional authors
Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin, R. L. Jones, R. G. Maki, S. R. Patel, G. Wang, T. A. McGowan, W. S. Shalaby, R. E. Knoblauch, M. von Mehren, and G. D. Demetri
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours, R. L. Jones, M. J. Ratain, P. J. O'Dwyer, L. L. Siu, J. Jassem, J. Medioni, M. DeJonge, C. Rudin, R. Maki, G. Schwartz, and +20 additional authors
An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab., M. Lee and N. Seetharamu
Novel HMGA2-YAP1 fusion gene in aggressive angiomyxoma, M. Y. Lee, B. Da Silva, D. C. Ramirez, and R. G. Maki
An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy, P. H. Liu, R. B. Shah, Y. Li, A. Arora, P. M. Ung, R. Raman, A. Gorbatenko, S. Kozono, R. G. Maki, S. Sidi, and +13 additional authors
Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung Cancer, E. Miao, N. Seetharamu, K. Sullivan, S. Eng, and C. S. Lee
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically, K. Mrózek, A. K. Eisfeld, J. Kohlschmidt, A. J. Carroll, C. J. Walker, D. Nicolet, J. S. Blachly, M. Bill, J. E. Kolitz, C. D. Bloomfield, and +7 additional authors
An unusual case of Kaposi sarcoma masquerading as cystitis in a kidney transplant recipient, V. Nair, F. Sheikh, D. Hirschwerk, A. Fahmy, M. Bhaskaran, E. Grodstein, A. Winnick, R. Maki, L. Teperman, and E. Molmenti
Prognostic and biologic relevance of clinically applicable long noncoding RNA profiling in older patients with cytogenetically normal acute myeloid leukemia, D. Papaioannou, D. Nicolet, H. G. Ozer, K. Mrozek, S. Volinia, P. Fadda, A. J. Carroll, J. Kohlschmidt, J. E. Kolitz, C. D. Bloomfield, and +4 additional authors
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma, S. Patel, M. von Mehren, D. R. Reed, P. Kaiser, J. Charlson, C. W. Ryan, D. Rushing, M. Livingston, R. G. Maki, G. D. Demetri, and +10 additional authors
Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors, M. A. Pulsipher, B. R. Logan, D. M. Kiefer, P. Chitphakdithai, M. L. Riches, D. Rizzo, P. Anderlini, R. Bayer, I. Sahdev, B. E. Shaw, and +51 additional authors
Acute kidney injury in hematopoietic stem cell transplantation, R. Wanchoo, B. R. Stotter, R. L. Bayer, and K. D. Jhaveri
Submissions from 2018
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib, J. C. Barrientos, J. A. Burger, J. C. Byrd, P. Hillmen, C. Zhou, J. Ninomoto, D. F. James, and T. J. Kipps
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL, J. R. Brown, P. Hillmen, S. O'Brien, J. C. Barrientos, N. M. Reddy, S. E. Coutre, C. S. Tam, S. P. Mulligan, U. Jaeger, J. C. Byrd, and +20 additional authors
A Method to Summarize Toxicity in Cancer Randomized Clinical Trials., M. Carbini, M. Suárez-Fariñas, and R. G. Maki
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors, D. R. D'Adamo, M. A. Dickson, M. L. Keohan, R. D. Carvajal, M. L. Hensley, C. M. Hirst, M. O. Ezeoke, L. Ahn, R. G. Maki, W. D. Tap, and +4 additional authors
TERT promoter mutations in solitary fibrous tumour, E. G. Demicco, K. Wani, D. Ingram, M. Wagner, R. G. Maki, A. Rizzo, A. Meeker, A. J. Lazar, and W. L. Wang
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: An analysis of Alliance studies, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, J. S. Blachly, C. J. Walker, D. Nicolet, S. Orwick, S. E. Maharry, J. E. Kolitz, C. D. Bloomfield, and +6 additional authors
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome, A. K. Eisfeld, J. Kohlschmidt, K. Mrózek, A. Mims, C. J. Walker, J. S. Blachly, D. Nicolet, S. Orwick, J. E. Kolitz, C. D. Bloomfield, and +7 additional authors
Clinical cancer advances 2018: Annual report on progress against cancer from the American Society of Clinical Oncology, J. Heymach, L. Krilov, A. Alberg, N. Baxter, S. M. Chang, R. Corcoran, W. Dale, A. DeMichele, R. G. Maki, H. Burstein, and +12 additional authors
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: Subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma, R. L. Jones, G. D. Demetri, S. M. Schuetze, M. Milhem, A. Elias, B. A. Van Tine, J. Hamm, S. McCarthy, R. G. Maki, M. Von Mehren, and +5 additional authors
Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment, J. A. Khan, R. G. Maki, and V. Ravi
Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia, J. E. Lancet, G. L. Uy, J. E. Cortes, L. F. Newell, T. L. Lin, E. K. Ritchie, R. K. Stuart, S. A. Strickland, J. E. Kolitz, B. C. Medeiros, and +11 additional authors
Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia, A. Ngankeu, P. Ranganathan, V. Havelange, D. Nicolet, S. Volinia, B. L. Powell, J. E. Kolitz, G. L. Uy, R. M. Stone, R. Garzon, and +4 additional authors
Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition, A. Pang, M. Carbini, A. L. Moreira, and R. G. Maki
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics, K. Runcie, D. R. Budman, V. John, and N. Seetharamu
Hybrid capture–based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus, A. B. Schrock, D. Pavlick, S. J. Klempner, J. H. Chung, B. Forcier, A. Welsh, L. Young, B. Leyland-Jones, C. Devoe, V. A. Miller, and +9 additional authors
Sarcoma: The Merging of Science and Clinical Care, G. K. Schwartz and R. G. Maki
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma, S. Stacchiotti, O. Mir, A. Le Cesne, B. Vincenzi, A. Fedenko, R. G. Maki, N. Somaiah, S. Patel, M. Brahmi, A. Kawai, and +13 additional authors
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer, H. Tiriac, P. Belleau, D. D. Engle, D. Plenker, A. Deschenes, D. V. Sejpal, J. D. Sullivan, J. M. Crawford, C. Devoe, D. A. Tuveson, and +60 additional authors
Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA, C. J. Walker, C. C. Oakes, L. K. Genutis, B. Giacopelli, S. Liyanarachchi, D. Nicolet, A. K. Eisfeld, M. Scholz, J. E. Kolitz, C. D. Bloomfield, and +12 additional authors
Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients, J. R. Wolf, C. E. Heckler, J. J. Guido, A. R. Peoples, J. S. Gewandter, M. Ling, V. P. Vinciguerra, T. Anderson, L. Evans, G. R. Morrow, and +2 additional authors
Submissions from 2016
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia, J. C. Byrd, B. Harrington, S. O'Brien, J. A. Jones, A. Schuh, S. Devereux, J. Chaves, W. G. Wierda, J. C. Barrientos, R. R. Furman, and +20 additional authors
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials, J. J. Castillo, F. Mulkey, S. Geyer, J. E. Kolitz, W. Blum, B. L. Powell, S. L. George, R. A. Larson, and R. M. Stone
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies, H. Raftopoulos, A. Laadem, P. J. Hesketh, J. Goldschmidt, N. Gabrail, C. Osborne, M. Ali, M. L. Sherman, D. Wang, J. Crawford, and +3 additional authors
Chronic lymphocytic leukemia (CLL) - Then and Now, K. R. Rai and P. Jain
A Phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: A Trial of the ECOG-ACRIN Cancer Research Group (E1908), C. S. Zent, X. V. Wang, R. P. Ketterling, C. A. Hanson, E. N. Libby, J. C. Barrientos, T. G. Call, J. E. Chang, J. J. Liu, M. S. Tallman, and +5 additional authors
Submissions from 2015
Adoption of a Uniform Start Date for Internal Medicine Fellowships and Other Advanced Training: An AAIM White Paper, J. C. Barrett, R. Alweis, M. Frank, A. O'Connor, J. F. McConville, N. D. Adams, L. Arfons, S. Bernard, T. Bradley, E. A. Muchmore, and +13 additional authors
Management of Chronic Lymphocytic Leukemia in the Elderly, J. C. Barrientos
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data, S. E. Bates, R. Eisch, A. Ling, D. Rosing, M. Turner, S. Pittaluga, H. M. Prince, M. H. Kirschbaum, S. L. Allen, R. L. Piekarz, and +15 additional authors
Clinical features, and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3), B. Bhatnagar, J. S. Blachly, J. Kohlschmidt, A. K. Eisfeld, S. Volinia, D. Nicolet, A. J. Carroll, A. M. Block, J. E. Kolitz, C. D. Bloomfield, and +3 additional authors
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia, J. R. Brown, J. C. Barrientos, P. M. Barr, I. W. Flinn, J. A. Burger, A. Tran, F. Clow, D. F. James, K. Rai, S. O'Brien, and +2 additional authors
Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine: daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML, J. E. Cortes, S. L. Goldberg, E. J. Feldman, D. A. Rizzeri, D. E. Hogge, M. Larson, A. Pigneux, C. Recher, G. Schiller, J. E. Kolitz, and +3 additional authors
Management of adverse events associated with idelalisib treatment: expert panel opinion, S. E. Coutre, J. C. Barrientos, J. R. Brown, S. de Vos, R. R. Furman, M. J. Keating, D. Li, S. M. O'Brien, J. M. Pagel, A. D. Zelenetz, and +3 additional authors
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: A phase I study in chronic lymphocytic leukemia, M. E. Kalaycio, O. G. Negrea, S. L. Allen, K. R. Rai, R. M. Abbasi, H. Horne, W. A. Wegener, and D. M. Goldenberg
Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo) Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer, I. E. Krop, T. M. Suter, C. T. Dang, L. Dirix, G. Romieu, C. Zamagni, M. L. Citron, M. Campone, N. Xu, M. Smitt, and L. Gianni
Integrating targeted drugs with taxanes and platinums: opportunities and challenges, D. Kudlowitz, E. Teplinsky, and F. Muggia
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance), J. A. Ligibel, C. T. Cirrincione, M. Liu, M. Citron, J. N. Ingle, W. Gradishar, S. Martino, W. Sikov, R. Michaelson, W. T. Barry, and +6 additional authors
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, R. C. Lindsley, B. G. Mar, E. Mazzola, P. V. Grauman, S. Shareef, S. L. Allen, A. Pigneux, M. Wetzler, R. K. Stuart, B. L. Ebert, and +9 additional authors
Introduction: moving beyond chemotherapy, F. Muggia and E. Teplinsky
Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome, B. Nazha, G. Garcia, R. Kandov, and M. Odaimi
Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue, B. R. Page, E. G. Shaw, L. Lu, D. Bryant, D. Grisell, G. J. Lesser, D. C. Monitto, M. J. Naughton, S. R. Savona, M. D. Chan, and +3 additional authors
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria, H. Raftopoulos, R. Boccia, W. Cooper, E. O'Boyle, and R. J. Gralla
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide, D. Sanford, F. Lo-Coco, M. A. Sanz, E. Di Bona, S. Coutre, J. K. Altman, M. Wetzler, S. L. Allen, F. Ravandi, H. Kantarjian, and J. E. Cortes
Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer, E. Sarafraz-Yazdi, C. Gorelick, A. R. Wagreich, G. Salame, M. Angert, C. H. Gartman, V. Gupta, W. B. Bowne, Y. C. Lee, J. Michl, and +2 additional authors
Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes, B. Sherry, P. Jain, P. Y. Chiu, L. Leung, S. L. Allen, J. E. Kolitz, K. R. Rai, J. Barrientos, S. Liang, R. Hawtin, and N. Chiorazzi
Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia, R. M. Stone, E. Mazzola, D. Neuberg, S. L. Allen, A. Pigneux, R. K. Stuart, M. Wetzler, D. Rizzieri, H. P. Erba, B. Powell, and +12 additional authors
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs, A. Tefferi, K. Rai, A. I. Schafer, C. Schiffer, M. A. Sekeres, L. L. Siu, F. M. Stewart, M. Thompson, J. M. Vose, P. H. Wiernik, and +109 additional authors
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?, E. Teplinsky and F. J. Esteva
EGFR and HER2: is there a role in ovarian cancer?, E. Teplinsky and F. Muggia
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia, E. Tiacci, J. H. Park, L. De Carolis, S. S. Chung, A. Broccoli, S. Scott, F. Zaja, S. Devlin, K. R. Rai, M. S. Tallman, and +31 additional authors
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results, M. L. Wang, K. A. Blum, P. Martin, A. Goy, R. Auer, B. S. Kahl, W. Jurczak, R. H. Advani, J. C. Barrientos, S. Rule, and +14 additional authors
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, W. H. Wilson, R. M. Young, R. Schmitz, Y. D. Yang, S. Pittaluga, G. Wright, C. J. Lih, P. M. Williams, J. C. Barrientos, L. M. Staudt, and +20 additional authors
Submissions from 2014
More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review, F. Badulescu, A. Badulescu, D. Paul, C. F. Popescu, and C. Florescu